Detalhe da pesquisa
1.
Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial.
Lancet
; 401(10384): 1267-1276, 2023 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36934733
2.
Biodistribution and toxicology evaluation of a recombinant measles Schwarz-based Lassa vaccine in cynomolgus macaques.
J Appl Toxicol
; 43(5): 719-733, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36480160
3.
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
Lancet
; 392(10165): 2718-2727, 2019 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30409443
4.
Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections.
Front Immunol
; 11: 592, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32373111
5.
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.
Gastroenterology
; 134(5): 1385-95, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18471515
6.
Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.
Lancet Infect Dis
; 15(5): 519-27, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25739878
7.
Improvements of lung function in cystic fibrosis.
Pediatr Pulmonol
; 33(4): 263-8, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11921455
8.
Negative expiratory pressure: a new tool for evaluating lung function in children?
Pediatr Pulmonol
; 35(3): 162-8, 2003 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12567383
9.
A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
Vaccine
; 31(36): 3718-25, 2013 Aug 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23742993
10.
Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51.
Vaccine
; 28(32): 5197-202, 2010 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-20541581
11.
Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study.
Vaccine
; 27(15): 2188-93, 2009 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-19200452
12.
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.
Vaccine
; 27(37): 5142-51, 2009 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-19559112
13.
Japanese encephalitis vaccines--needs, flaws and achievements.
Biol Chem
; 389(5): 547-50, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18953721
14.
Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51.
Vaccine
; 26(48): 6151-6, 2008 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-18804132
15.
Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients.
Vaccine
; 25(37-38): 6793-806, 2007 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-17686555
16.
A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.
Vaccine
; 25(17): 3445-53, 2007 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-17241714
17.
Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.
Vaccine
; 24(20): 4343-53, 2006 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16581161